Nothing Special   »   [go: up one dir, main page]

CY1109961T1 - Χρηση διϋδροϊμιδαζολονων για την αγωγη της επιληψιας στους σκυλους - Google Patents

Χρηση διϋδροϊμιδαζολονων για την αγωγη της επιληψιας στους σκυλους

Info

Publication number
CY1109961T1
CY1109961T1 CY20091100314T CY091100314T CY1109961T1 CY 1109961 T1 CY1109961 T1 CY 1109961T1 CY 20091100314 T CY20091100314 T CY 20091100314T CY 091100314 T CY091100314 T CY 091100314T CY 1109961 T1 CY1109961 T1 CY 1109961T1
Authority
CY
Cyprus
Prior art keywords
dogs
differrimazazones
egyptian
adjustment
awd
Prior art date
Application number
CY20091100314T
Other languages
English (en)
Inventor
Chris Rundfeldt
Rita Dost
Wolfgang Löscher
Andrea Tipold
Klaus Unverferth
Hans-Joachim Lankau
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of CY1109961T1 publication Critical patent/CY1109961T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στη χρήση υποκατεστημένων διϋδροϊμιδαζολονών, συγκεκριμένα της [1-(4-χλωροφαινυλ)-4(4-μορφολινυλ)-2,5-διϋδρο-1Η-ιμιδαζολόνης] (AWD 131-138) ή ενός φυσιολογικά αποδεκτού άλατος αυτής για την αγωγή της επιληψίας στους σκύλους.
CY20091100314T 2002-10-10 2009-03-20 Χρηση διϋδροϊμιδαζολονων για την αγωγη της επιληψιας στους σκυλους CY1109961T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41759002P 2002-10-10 2002-10-10
EP03757945A EP1553952B1 (en) 2002-10-10 2003-10-09 Use of dihydroimidazolones for the treatment of epilepsy in dogs

Publications (1)

Publication Number Publication Date
CY1109961T1 true CY1109961T1 (el) 2014-09-10

Family

ID=32094042

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20091100314T CY1109961T1 (el) 2002-10-10 2009-03-20 Χρηση διϋδροϊμιδαζολονων για την αγωγη της επιληψιας στους σκυλους
CY2013031C CY2013031I2 (el) 2002-10-10 2013-07-11 Χρηση διϋδροϊμιδαζολονων για την αγωγη της επιληψιας στους σκυλους
CY20221100250T CY1125103T1 (el) 2002-10-10 2022-03-31 Χρηση διυδροïμιδαζολονων για την αγωγη σκυλων

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY2013031C CY2013031I2 (el) 2002-10-10 2013-07-11 Χρηση διϋδροϊμιδαζολονων για την αγωγη της επιληψιας στους σκυλους
CY20221100250T CY1125103T1 (el) 2002-10-10 2022-03-31 Χρηση διυδροïμιδαζολονων για την αγωγη σκυλων

Country Status (28)

Country Link
US (5) US20050070537A1 (el)
EP (3) EP1553952B1 (el)
JP (4) JP4694202B2 (el)
KR (2) KR101110587B1 (el)
CN (2) CN1726040B (el)
AR (1) AR041573A1 (el)
AT (1) ATE418337T1 (el)
AU (2) AU2003273978B2 (el)
BE (1) BE2013C046I2 (el)
BR (1) BR0315225A (el)
CA (2) CA2727722C (el)
CY (3) CY1109961T1 (el)
DE (1) DE60325496D1 (el)
DK (2) DK1553952T3 (el)
ES (2) ES2908453T3 (el)
FR (2) FR13C0044I2 (el)
HK (1) HK1085920A1 (el)
HR (3) HRP20090667B1 (el)
HU (2) HUS1300035I1 (el)
LU (1) LU92238I2 (el)
MX (1) MXPA05003663A (el)
NZ (1) NZ539864A (el)
PL (2) PL238776B1 (el)
PT (2) PT2845594T (el)
SI (2) SI2845594T1 (el)
TW (2) TWI324067B (el)
WO (1) WO2004032938A1 (el)
ZA (1) ZA200502245B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
UA87982C2 (ru) * 2003-07-11 2009-09-10 Берингер Ингельхайм Ветмедика Гмбх Способ лечения или предотвращения расстройств центральной нервной системы производными 1-ар(алк)-4-пиперидиноимидазолин-2-она, фармацевтическая композиция
AU2012296925A1 (en) 2011-08-12 2014-02-06 Boehringer Ingelheim Vetmedica Gmbh Taste masked pharmaceutical composition
JP6193613B2 (ja) * 2013-05-10 2017-09-06 学校法人麻布獣医学園 てんかん発作のモニタリングシステム及びモニタリング方法
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
CN106459030B (zh) 2014-05-28 2019-01-29 东亚荣养株式会社 取代托品烷衍生物
EP3193862B1 (en) 2014-09-16 2023-10-18 Igc Pharma Ip, Llc Topical cannabinoid composition for treating arthritic pain
WO2016118391A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2017027651A1 (en) 2015-08-12 2017-02-16 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044021A (en) 1971-10-21 1977-08-23 American Cyanamid Company Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
US3932452A (en) 1975-02-07 1976-01-13 Morton-Norwich Products, Inc. 1-Arylmethyl-2-imidazolidinones
DE19532668A1 (de) 1995-09-05 1997-03-06 Dresden Arzneimittel Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung
US5869481A (en) 1995-09-05 1999-02-09 Arzneitmittelwerk Dresden G.M.B.H. Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19721580A1 (de) * 1997-05-23 1998-11-26 Dresden Arzneimittel Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen
EP0991614A1 (en) * 1997-06-26 2000-04-12 Board of Regents, The University of Texas System Synthesis of dihydrohonokiol compositions
JP4669095B2 (ja) * 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
NZ535663A (en) 2002-03-07 2006-06-30 Boehringer Ingelheim Pharma Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester and the salts thereof
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
AU2012296925A1 (en) 2011-08-12 2014-02-06 Boehringer Ingelheim Vetmedica Gmbh Taste masked pharmaceutical composition
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals

Also Published As

Publication number Publication date
JP2016104817A (ja) 2016-06-09
BE2013C046I2 (el) 2022-08-09
TW200503726A (en) 2005-02-01
SI1553952T1 (sl) 2009-04-30
CA2501772A1 (en) 2004-04-22
FR13C0044I1 (el) 2013-08-30
AU2009225322A1 (en) 2009-11-05
DK2845594T3 (da) 2022-03-07
HUS1300035I1 (hu) 2017-10-30
LU92238I9 (el) 2019-01-09
PT1553952E (pt) 2009-02-10
BR0315225A (pt) 2005-08-23
CY1125103T1 (el) 2023-01-05
KR20110063843A (ko) 2011-06-14
JP2006503873A (ja) 2006-02-02
HRP20200207A2 (hr) 2020-07-24
HRP20090667A2 (hr) 2010-07-31
ES2908453T3 (es) 2022-04-29
PL374603A1 (en) 2005-10-31
CN101890019A (zh) 2010-11-24
WO2004032938A1 (en) 2004-04-22
ZA200502245B (en) 2005-11-30
NZ539864A (en) 2007-11-30
PL397320A1 (pl) 2012-02-13
JP2011068685A (ja) 2011-04-07
US20150072983A1 (en) 2015-03-12
PL238776B1 (pl) 2021-10-04
HRP20050322B1 (hr) 2013-12-06
US8859540B2 (en) 2014-10-14
US9469611B2 (en) 2016-10-18
CA2727722C (en) 2013-05-28
ATE418337T1 (de) 2009-01-15
EP2845594A1 (en) 2015-03-11
ES2316808T3 (es) 2009-04-16
HRP20050322A2 (en) 2006-05-31
HRP20090667B1 (hr) 2021-06-11
PL214702B1 (pl) 2013-09-30
SI2845594T1 (sl) 2022-04-29
AU2003273978A1 (en) 2004-05-04
TWI324067B (en) 2010-05-01
MXPA05003663A (es) 2005-06-08
CA2501772C (en) 2011-08-23
FR22C1033I1 (fr) 2022-09-09
EP2845594B1 (en) 2022-02-23
HK1085920A1 (en) 2006-09-08
US8962617B2 (en) 2015-02-24
TWI424849B (zh) 2014-02-01
PT2845594T (pt) 2022-03-09
DK1553952T3 (da) 2009-04-20
JP6249812B2 (ja) 2017-12-20
EP2036563A1 (en) 2009-03-18
KR101110587B1 (ko) 2012-02-15
EP1553952B1 (en) 2008-12-24
AU2003273978B2 (en) 2009-07-23
LU92238I2 (fr) 2013-09-03
TW201010706A (en) 2010-03-16
CN1726040A (zh) 2006-01-25
US20050070537A1 (en) 2005-03-31
EP1553952A1 (en) 2005-07-20
JP4694202B2 (ja) 2011-06-08
AR041573A1 (es) 2005-05-18
KR20050056237A (ko) 2005-06-14
CA2727722A1 (en) 2004-04-22
US20130065898A1 (en) 2013-03-14
JP2014080449A (ja) 2014-05-08
DE60325496D1 (de) 2009-02-05
CY2013031I1 (el) 2015-11-04
CY2013031I2 (el) 2015-11-04
CN1726040B (zh) 2010-05-12
US20080027057A1 (en) 2008-01-31
US20160367562A1 (en) 2016-12-22
HUS2200036I1 (hu) 2022-08-28
FR13C0044I2 (fr) 2014-03-07

Similar Documents

Publication Publication Date Title
CY1109961T1 (el) Χρηση διϋδροϊμιδαζολονων για την αγωγη της επιληψιας στους σκυλους
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
NO20052512L (no) Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander
IL180147A0 (en) N - (1 - (1 - benzyl - 4 - phenyl - 1h-imidazol - 2 - yl) - 2,2 - dymethylpropyl) benzamide derivatives and related compounds as kinesin spidle protein (ksp) inhibitors for the treatment of cancer
DK1318992T3 (da) Imidazolderivater som Raf-kinaseinhibitorer
ITTO20020775A1 (it) Schienale di sedia.
EA200600203A1 (ru) Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
ITTO20030185A1 (it) Stabilizzazione migliorata del disassamento per alesatori eccentrici.
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
DK3632902T3 (da) 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom
ATE516275T1 (de) Microbiozide (z.b. fungizide) 1,2,3- triazolderivate
EA200701164A1 (ru) Способ получения аннелированных производных пиперазин-2-она и соответствующие промежуточные продукты
DE60127537D1 (de) VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
EA200600833A1 (ru) Тиазолидиноны, их получение и применение как фармацевтических агентов
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
ITTO20020867A1 (it) Schienale di sedia.
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
ITBO20020678A0 (it) Manipolo dentale per la rimozione del tartaro.
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
DE602004003252D1 (de) Verwendung von 2h-ä1,3ü-oxazinoä3,2-aüindol-derivaten zur behandlung von neuropathischem schmerz
ES2328328A1 (es) Polimorfo alfa de una pirazolina sustituida, su preparacion y su uso como medicamento